Can nadolol cause cough and wheeze?

Can Nadolol Cause Cough and Wheeze?

Yes, nadolol can cause both cough and wheeze, particularly bronchospasm, which is a recognized adverse effect occurring in approximately 1 in 1,000 patients, and nadolol is contraindicated in patients with bronchial asthma and should be avoided in those with reactive airway disease. 1, 2

Mechanism and Clinical Evidence

Nadolol is a non-cardioselective beta-blocker, meaning it blocks both beta-1 and beta-2 receptors 2. The beta-2 receptors in the lungs are responsible for bronchodilation, so blocking them can lead to:

• Bronchospasm (wheezing)
• Bronchoconstriction
• Cough (listed as an adverse effect in FDA labeling) 1

The FDA drug label explicitly lists:

• Bronchospasm as occurring in approximately 1 of 1,000 patients 1
• Cough and nasal stuffiness among miscellaneous adverse effects occurring in 1 to 5 of 1,000 patients 1
• Respiratory distress as a potential allergic reaction 1

Guideline Recommendations and Contraindications

Absolute contraindication: Nadolol is contraindicated in bronchial asthma 1

Relative contraindications and cautions:

• Should be avoided in patients with reactive airways disease 2
• The 2017 ACC/AHA hypertension guidelines specifically note to "avoid in patients with reactive airways disease" 2
• The 2015 ACC/AHA/HRS SVT guidelines list reactive airway disease as a precaution requiring exclusion or cautious use 3

Clinical Context from Research

While beta-blockers as a class are recognized causes of drug-induced cough 4, the evidence is nuanced:

• General beta-blocker effects: Beta-blockers can cause chronic dry cough and bronchospasm 4
• Nadolol-specific data: One small pilot study in 10 patients with mild asthma showed nadolol was "well tolerated" in 8 of 10 subjects, though there was a 5% reduction in FEV1 5. However, 2 patients with reactive airway disease developed wheezing requiring discontinuation 6

Important Clinical Pitfalls

1. Non-selective vs. cardioselective: Unlike cardioselective beta-blockers (atenolol, metoprolol, bisoprolol) that are "preferred in patients with bronchospastic airway disease requiring a beta blocker" 2, nadolol blocks both beta-1 and beta-2 receptors, making respiratory side effects more likely

2. Delayed recognition: Drug-induced cough may be misdiagnosed as COPD exacerbations or respiratory infections 7, leading to inappropriate treatment

3. Management: If nadolol-induced cough or wheeze is suspected, discontinue the drug 4. Cough typically resolves within 1-4 weeks after drug withdrawal 8

Alternative Approach

If a beta-blocker is absolutely necessary in a patient with borderline or mild reactive airway disease:

• Consider cardioselective agents (atenolol, metoprolol, bisoprolol) instead 2
• The guidelines note these can be used "cautiously, with careful monitoring of pulmonary status" in patients with quiescent bronchospastic asthma where heart rate control is essential 9
• Nadolol should not be the beta-blocker of choice in this population